IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA) WITH THERAPEUTIC SERUM LEVELS, A CHANGE IN BIOTHERAPY CLASS IS GREATER THAN AN INTENSIFICATION OF ADA DOSE IN PATIENTS WITH CROHN´S DISEASE AND HEMORRHAGIC RECTOCOLITIS

Capucine Genin  ¹     Nicolas Williet  ²     Anne Emmanuelle Berger  ³     Pauline Veyrard  ³     Jean Marc Phelip  ³     Gilles Boschetti  ⁴     Stephane NANCEY  ⁵     Stéphane Paul  ⁵     Xavier Roblin  ^5    
1 University of St. Etienne, Saint Etienne, France
² CHU St. Etienne, Saint-Priest-en-Jarez, France
³ Hôpital Nord, Saint Etienne, France
⁴ Hospital Lyon-Sud, Pierre-Benite, France
⁵ CHU Lyon, Pierre-Benite, France

Session
IBD (Posters)

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)